Sustained-release pramipexole in the treatment of Parkinson’s disease
Dopamine (DA) receptor agonists ensure stimulation of DA receptors in the brain, by compensating for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early and extensive PD stages; its clinical efficacy has been proven in many double-blind randomize...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-03-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/343 |